


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-7. (cancelled)

8. (new) A compound according to formula I:



wherein,

X is oxygen, sulphur or a NR⁷ group;

R¹ is C₃-C₈ alkyl or C₁-C₈ alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C₁-C₆ alkyl, hydroxyl, or C₁-C₆ alkoxy;

R² and R³ are independently hydrogen, C₁-C₆ alkyl, halogen, trifluoromethyl, hydroxy or C₁-C₆ alkoxy;

R⁴ is hydrogen or C₁-C₈ alkyl;

R⁵ and R⁶ are independently hydrogen or C₁-C₃ alkyl, optionally substituted by hydroxy or phenyl;

R⁷ is hydrogen or straight or branched C₁-C₃ alkyl;

Het is a five to seven membered, saturated or unsaturated, heteromonocyclic or an eight to ten membered, saturated or unsaturated, heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said monocyclic or bicyclic groups being optionally substituted by C₁-C₆ alkyl, halogen, hydroxyl or C₁-C₆ alkoxy; or the pharmaceutically acceptable salts thereof,

with the proviso that:

Het cannot be indole, benzo[b]furan, benzo[b]thiophen, chroman, when R⁵ and R⁶ are both hydrogen, or Het cannot be 2-pyridyl;

when R¹ is unsubstituted or substituted benzyl, and R² and R³ are hydrogen, halogen or alkoxy, R⁴ is other than hydrogen;

when R¹ is propyl or butyl, R², R³, R⁵ and R⁶ are hydrogen and R⁴ is hydrogen, methyl or ethyl, Het cannot be 1,4-benzodioxan;


when X- R¹ is a para butyloxy group and R², R³, R⁴, R⁵ and R⁶ are hydrogen, Het cannot be 2-thiophenyl, or 4-(2,2'-dimethyl)-pyranlyl;

when X- R¹ is an ortho heptyloxy or octyloxy group and R², R³, R⁴, R⁵ and R⁶ are hydrogen, Het cannot be 2-furyl; and

when X- R¹ is an ortho O-(CH₂)_m-p-CF₃-phenyl group, where m is an integer from 1 to 3, and R², R³, R⁵ and R⁶ are hydrogen, Het cannot be pyridyl.

9. (new) A medicament having sodium and/or calcium channel modulating activity and/or selective MAO-B inhibiting activity, said medicament comprising:

a compound according to formula I:



wherein,

R¹ is C₃-C₈ alkyl or C₁-C₈ alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C₁-C₆ alkyl, hydroxyl, or C₁-C₆ alkoxy,

R² and R³ are independently hydrogen, C₁-C₆ alkyl, halogen, trifluoromethyl, hydroxy or C₁-C₆ alkoxy,

R⁴ is hydrogen or C₁-C₈ alkyl,

R⁵ and R⁶ are independently hydrogen or C₁-C₃ alkyl, optionally substituted by hydroxy or phenyl,

R^7 is hydrogen or straight or branched C_1 - C_3 alkyl,

Het is a five to seven membered, saturated or unsaturated, heteromonocyclic or an eight to ten membered, saturated or unsaturated, heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said monocyclic or bicyclic groups being optionally substituted by C_1 - C_6 alkyl, halogen, hydroxyl or C_1 - C_6 alkoxy, or

the pharmaceutically acceptable salts thereof,

with the proviso that:

Het cannot be an indole, chroman when R^5 and R^6 are both hydrogen,

when X - R^1 is an ortho $O-(CH_2)_m$ -p- CF_3 -phenyl group, where m is an integer from 1 to 3, and R^2 , R^3 , R^5 and R^6 are hydrogen, Het cannot be pyridyl or the pharmaceutically acceptable salts or prodrug thereof.

10. (new) The medicament according to claim 9, wherein for the compound according to formula I:

R^1 is benzyl or C_5 - C_8 alkyl,

R^4 , R^5 and R^6 are hydrogen or C_1 - C_3 alkyl,

X is oxygen, and

Het is furan, tetrahydrofuran, isoxazol, oxazol, thiophen, pyran, or dioxane, unsubstituted or substituted by C_1 - C_3 alkyl.

11. (new) The medicament according to claim 9, wherein the compound according to formula I is selected from the group consisting of:

(4-Pentyloxy-benzyl)-(furan-2-ylmethyl)-amine;
(4-Heptyloxy-benzyl)-(furan-2-ylmethyl)-amine;
(R) (4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-
amine;
(S) (4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-
amine;
(R) (4-Heptyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-
amine;
(S) (4-Heptyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-
amine;
(R) (4-Pentyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-
amine;
(S) (4-Pentyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-
amine;
(R) (4-Heptyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-
amine;
(S) (4-Heptyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-
amine;
(4-Benzyloxy-benzyl)-(furan-2-ylmethyl)-amine;
(4-Benzyloxy-benzyl)-(5-methyl-furan-2-ylmethyl)-amine;
[4-(3-Fluoro-benzyloxy)-benzyl]-(furan-2-ylmethyl)-
amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(furan-2-ylmethyl)-
amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(5-methyl-furan-2-
ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(5-methyl-furan-2-
ylmethyl)-amine;

(R) (4-Benzyloxy-benzyl)-[1-(furan-2-yl)-1-ethyl]-amine;

(S) (4-Benzyloxy-benzyl)-[1-(furan-2-yl)-1-ethyl]-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-[1-(furan-2-yl)-1-
ethyl]-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-[1-(furan-2-yl)-1-
ethyl]-amine;

(R) (4-Benzyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-
amine;

(S) (4-Benzyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-
amine;

(R) [4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-furan-2-
ylmethyl)-amine;

(S) [4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-furan-2-
ylmethyl)-amine;

(R) [4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-furan-2-
ylmethyl)-amine;

(S) [4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-furan-2-
ylmethyl)-amine;

(R) [4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(S) [4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(R) [4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(S) [4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(1,4-dioxan-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(pyrido-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(pyrido-3-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(pyrido-4-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(imidazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(1-methyl-imidazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(5-methyl-1H-triazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(4-methyl-thiazol-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(isoxazol-5-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(isoxazol-5-ylmethyl)-
amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(isoxazol-5-ylmethyl)-
amine;

(4-Benzyloxy-benzyl)-(3-methyl-isoxazol-5-ylmethyl)-
amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(3-methyl-isoxazol-5-
ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(3-methyl-isoxazol-5-
ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(oxazol-2-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(oxazol-2-ylmethyl)-
amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(oxazol-2-ylmethyl)-
amine;

(4-Benzyloxy-benzyl)-(oxazol-5-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(oxazol-5-ylmethyl)-
amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(oxazol-5-ylmethyl)-
amine;

(4-Benzyloxy-benzyl)-(thiophen-2-ylmethyl)-amine;

[2-(3-Chloro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-
amine;

[2-(3-Fluoro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-
amine;

[3-(3-Chloro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-
amine;

[3-(3-Fluoro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-
amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-
amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-
amine;

[2-(3-Fluoro-benzyloxy)-benzyl]-(benzo[b]furan-2-
ylmethyl)-amine;

[3-(3-Fluoro-benzyloxy)-benzyl]-(benzo[b]furan-2-
ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(benzo[b]furan-2-
ylmethyl)-amine;

(R) [4-(3-Fluoro-benzyloxy)-benzyl]-(dihydro-
benzo[b]furan-2-ylmethyl)-amine;


(S) [4-(3-Fluoro-benzyloxy)-benzyl]-(dihydro-
benzo[b]furan-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(benzimidazol-2-
ylmethyl)-amine;

either as a single isomer or as a mixture of isomers
thereof, or the pharmaceutically acceptable salts thereof.

12. (new) A process for the preparation of a compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, the process comprising:

a) reacting a compound of formula II



II


wherein

X is oxygen, sulphur or a NR⁷ group,

R¹ is C₃-C₈ alkyl or C₁-C₈ alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluotomethyl, C₁-C₆ alkyl, hydroxyl, or C₁-C₆ alkoxy,

R² and R³ are independently hydrogen, C₁-C₆ alkyl, halogen, trifluoromethyl, hydroxy or C₁-C₆ alkoxy,

with a compound of formula III



III

wherein

R⁴ is hydrogen or C₁-C₈ alkyl,

R⁵ and R⁶ are independently hydrogen or C₁-C₃ alkyl,
optionally substituted by hydroxy or phenyl,

R⁷ is hydrogen or straight or branched C₁-C₃ alkyl,

Het is a five to seven membered, saturated or
unsaturated, heteromonocyclic or an eight to ten membered,
saturated or unsaturated, heterobicyclic group, containing one or
more heteroatoms chosen independently from nitrogen, oxygen and
sulphur, said monocyclic or bicyclic groups being optionally
substituted by C₁-C₆ alkyl, halogen, hydroxyl or C₁-C₆ alkoxy,

with the proviso that:

Het cannot be indole, benzo[b]furan, benzo[b]thiophen,
chroman, when R⁵ and R⁶ are both hydrogen, or Het cannot be 2-
pyridyl,


when R¹ is unsubstituted or substituted benzyl, and R²
and R³ are hydrogen, halogen or alkoxy, R⁴ is other than
hydrogen,

when R¹ is propyl or butyl, R², R³, R⁵ and R⁶ are
hydrogen and R⁴ is hydrogen, methyl or ethyl, Het cannot be 1,4-
benzodioxan,

when X- R¹ is a para butyloxy group and R², R³, R⁴, R⁵
and R⁶ are hydrogen, Het cannot be 2-thiophenyl, or 4-(2,2'-
dimethyl)-pyranyl,

when X- R¹ is an ortho heptyloxy or octyloxy group and

R^2 , R^3 , R^4 , R^5 and R^6 are hydrogen, Het cannot be 2-furyl, and
when $X-R^1$ is an ortho $O-(CH_2)_m-p-CF_3$ -phenyl group,
where m is an integer from 1 to 3, and R^2 , R^3 , R^5 and R^6 are
hydrogen, Het cannot be pyridyl,
in the presence of a reducing agent, or
b) reacting a compound of formula III as defined above
with a compound of formula IV,



wherein

X is oxygen, sulphur or a NR^7 group,
 R^1 is C_3-C_8 alkyl or C_1-C_8 alkyl substituted by phenoxy
or phenyl, both phenoxy or phenyl being optionally substituted by
one or more fluoro, chloro, trifluoromethyl, C_1-C_6 alkyl,
hydroxyl, or C_1-C_6 alkoxy,

R^2 and R^3 are independently hydrogen, C_1-C_6 alkyl,
halogen, trifluoromethyl, hydroxy or C_1-C_6 alkoxy,

Y is a halogen atom or a $O-EWG$ group, where the EWG
means an electron withdrawing group, able to transform the oxygen
to which the group is linked, into a leaving group and,
optionally, converting a compound of the invention into another
compound of the invention and/or, optionally, converting the

compound of formula IV into a pharmaceutically acceptable salt and/or, optionally, converting a salt into a free compound.

13. (new) A pharmaceutical composition comprising:

the compound according to claim 8, as an active principle, or a pharmaceutically acceptable salt thereof; and

a suitable carrier and/or diluent and optionally other therapeutic agents.